Condition (MeSH)
Erythroblastosis, Fetal
ClinicalTrials.gov lists 30 trials for Erythroblastosis, Fetal or a narrower condition beneath it.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
11 of the 30 trials are tagged with Erythroblastosis, Fetal itself; the rest are tagged with a narrower condition beneath it.
When did Erythroblastosis, Fetal trials start? (17)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 2
- Phase 2/3
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 3
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 2 |
| 2025 | 1 |
| 2024 | 2 |
| 2022 | 2 |
| 2021 | 3 |
| 2020 | 2 |
| 2019 | 2 |
| 2018 | 3 |
| 2017 | 3 |
| 2016 | 2 |
Showing 10 of 17 earlier years.
No forecast is made for this condition: it averages 1.6 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: none of the 30 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Erythroblastosis, Fetal trials in? (7)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 2 |
| Phase 2/3 | 1 |
| Phase 3 | 2 |
| Phase 4 | 1 |
| Not applicable | 10 |
| Observational | 13 |
How many Erythroblastosis, Fetal trials are recruiting? (8)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 3 |
| Recruiting | 4 |
| Enrolling by invitation | 1 |
| Active, not recruiting | 2 |
| Completed | 11 |
Showing 5 of 8 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Erythroblastosis, Fetal trials? (4)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | 1 |
| InfaCare Pharmaceuticals Corporation, a Mallinckrodt Company | 1 |
| Janssen Research & Development, LLC | 1 |
| Ministry of Health, Saudi Arabia | 1 |
Which drugs are being tested for Erythroblastosis, Fetal? (2)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| tin mesoporphyrin | 2 |
| Immunoglobulin | 1 |
Interventions as named in the registry (5)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| darbepoetin alfa SF | 1 |
| usual prescribed intralipid (UL) regimen | 1 |
| in utero hematopoietic stem cell transplantation | 1 |
| SHAM injection | 1 |
| restricted prescribed intralipid (RL) regimen | 1 |
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which publications cover Erythroblastosis, Fetal? (26)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Infant Immunity after Maternal Nipocalimab in Severe Hemolytic Disease of the Fetus and Newborn. | NEJM evidence | 2026 | Yes |
| Nipocalimab in Early-Onset Severe Hemolytic Disease of the Fetus and Newborn. | The New England journal of medicine | 2024 | Yes |
| ABO hemolytic disease of the newborn: a need for clarity and consistency in diagnosis. | Journal of perinatology : official journal of the California Perinatal Association | 2023 | Yes |
| History and current standard of postnatal management in hemolytic disease of the fetus and newborn. | European journal of pediatrics | 2023 | Yes |
| Hemolytic Disease of the Fetus and Newborn: Historical and Current State. | Clinics in laboratory medicine | 2021 | Yes |
Showing 5 of 26 publications.
Sub-conditions in MeSH (2)
MeSH descendants one level down with at least one trial, most trials first.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: serious adverse events in this condition's trials, prevalence, and rare-disease identity.